References: 1. ZOMETA^® Summary of Product Characteristics. Novartis Pharma AG. 2. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314-3321. 3. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387. 4. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumours: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621. 5. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882. 6. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664. 7. Keller ET, Dai J, Escara-Wilke J, et al. New trends in the treatment of bone metastasis. J Cell Biochem. 2007;102:1095-1102. 8. Smith JA Jr, Soloway MS,Young MJ. Complications of advanced prostate cancer. Urology. 1999;54(suppl 6A):8-14. 9. Schran H, Ravera C, Skerjanec A, Boisclair M. Regular dosing of zoledronic acid maintains continuous suppression of osteolysis in patients with malignant bone disease. Presented at: International Bone & Mineral Society Davos Workshops;9-14 March 2008; Davos, Switzerland. Abstract 199. 10. Hatoum HT, Lin S-J, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumours and bone metastases: analysis of a national medical claims database. Cancer. 2008;113:1438-1445. 11. Data on file. Novartis Pharma AG.